{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:56:55Z","timestamp":1758970615680,"version":"3.37.3"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M631179"],"award-info":[{"award-number":["2018M631179"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central University Basic Research Fund","award":["2015qngz05"],"award-info":[{"award-number":["2015qngz05"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224580","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T14:06:14Z","timestamp":1575295574000},"page":"e0224580","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China"],"prefix":"10.1371","volume":"14","author":[{"given":"Minghuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce Hoi-sze","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinglong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuxin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-2007","authenticated-orcid":true,"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"pone.0224580.ref001","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4158\/EP161199.RA","article-title":"The diabetes epidemic in China: an integrated review of national surveys","volume":"22","author":"X Shen","year":"2016","journal-title":"Endocr Pract"},{"key":"pone.0224580.ref002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/dmrr.2827","article-title":"Standards of care for type 2 diabetes in China","volume":"32","author":"J Weng","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"pone.0224580.ref003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabet.2017.11.002","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: benefit or risk?","volume":"44","author":"M Leggio","year":"2018","journal-title":"Diabetes Metab"},{"key":"pone.0224580.ref004","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"C Baigent","year":"2009","journal-title":"Lancet"},{"key":"pone.0224580.ref005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"JJ McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0224580.ref006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"JM Gaziano","year":"2018","journal-title":"Lancet"},{"key":"pone.0224580.ref007","doi-asserted-by":"crossref","first-page":"e13001","DOI":"10.1111\/eci.13001","article-title":"Aspirin in primary prevention for patients with diabetes: Still a matter of debate","volume":"48","author":"A Bonaventura","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"pone.0224580.ref008","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"L Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0224580.ref009","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dme.13133","article-title":"Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials","volume":"34","author":"SK Kunutsor","year":"2017","journal-title":"Diabet Med"},{"key":"pone.0224580.ref010","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"10","author":"DK Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"pone.0224580.ref011","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3111\/13696998.2010.499731","article-title":"A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention","volume":"13","author":"L Annemans","year":"2010","journal-title":"J Med Econ"},{"key":"pone.0224580.ref012","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"H Ogawa","year":"2008","journal-title":"JAMA"},{"volume-title":"Decision modelling for health economic evaluation","year":"2008","author":"A Briggs","key":"pone.0224580.ref013"},{"volume-title":"China Health Statistics Yearbook 2018","year":"2018","author":"National Health Commission of the People\u2019s Republic of China","key":"pone.0224580.ref014"},{"key":"pone.0224580.ref015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"AN Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"pone.0224580.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8400","article-title":"Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation","volume":"8","author":"C Main","year":"2004","journal-title":"Health Technol Assess"},{"key":"pone.0224580.ref017","doi-asserted-by":"crossref","first-page":"e56459","DOI":"10.1371\/journal.pone.0056459","article-title":"Gender differences in 1-year clinical characteristics and outcomes after stroke: results from the China National Stroke Registry","volume":"8","author":"Z Wang","year":"2013","journal-title":"PLoS One"},{"key":"pone.0224580.ref018","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/eurheartj\/ehs149","article-title":"Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study","volume":"34","author":"E Nikolic","year":"2013","journal-title":"Eur Heart J"},{"key":"pone.0224580.ref019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002321","article-title":"Cost-effectiveness of a statewide campaign to promote aspirin use for primary prevention of cardiovascular disease","volume":"4","author":"TL Michaud","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"pone.0224580.ref020","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","article-title":"Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk","volume":"117","author":"JP Greving","year":"2008","journal-title":"Circulation"},{"key":"pone.0224580.ref021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0272989X15606903","article-title":"Valuing health-realted quality of life in type 2 diabetes patients in China","volume":"36","author":"CW Pan","year":"2016","journal-title":"Med Decis Making"},{"key":"pone.0224580.ref022","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/clpt.2011.303","article-title":"A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention","volume":"91","author":"GF Guzauskas","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0224580.ref023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cdtm.2018.01.001","article-title":"In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation","volume":"4","author":"SS Chang","year":"2018","journal-title":"Chronic Dis Transl Med"},{"key":"pone.0224580.ref024","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1007\/s12325-018-0823-9","article-title":"Cost-effectiveness of primary prevention with statin treatment for Chinese patients with type 2 diabetes","volume":"35","author":"T Li","year":"2018","journal-title":"Adv Ther"},{"key":"pone.0224580.ref025","unstructured":"National Bureau of Statistics of China. 2019 [cited 2019 Jan 3]. Database [Internet]. Available from http:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01."},{"key":"pone.0224580.ref026","unstructured":"World Health Organization. Geneva: The World Health Report 2002: reducing risks, promoting healthy life; 2002."},{"key":"pone.0224580.ref027","unstructured":"International Monetary Fund. People\u2019s Republic of China. 2019 Apr [cited 12 April]. In: Counrty news at a glance [Internet]. Available from: https:\/\/www.imf.org\/en\/Countries\/CHN."},{"key":"pone.0224580.ref028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCOUTCOMES.114.001330","article-title":"Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction","volume":"8","author":"K Ito","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"pone.0224580.ref029","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.clinthera.2012.04.004","article-title":"Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease","volume":"34","author":"D Shiffman","year":"2012","journal-title":"Clin Ther"},{"key":"pone.0224580.ref030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00019053-200624020-00005","article-title":"A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease","volume":"24","author":"M Lamotte","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"pone.0224580.ref031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12962-016-0059-y","article-title":"Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis","volume":"14","author":"MT Tolla","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"issue":"164","key":"pone.0224580.ref032","first-page":"836","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"21","author":"U.S. Preventive Services Task Force","year":"2016","journal-title":"Ann Intern Med"},{"key":"pone.0224580.ref033","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/CIR.0b013e3181e3b133","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation","volume":"121","author":"M Pignone","year":"2010","journal-title":"Circulation"},{"key":"pone.0224580.ref034","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"MF Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0224580.ref035","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11606-013-2465-6","article-title":"Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men","volume":"28","author":"M Pignone","year":"2013","journal-title":"J Gen Intern Med"},{"key":"pone.0224580.ref036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.2015","article-title":"Health benefits and cost-effectiveness of asymptomatic screening for hypertension and high cholesterol and aspirin counseling for primary prevention","volume":"15","author":"SP Dehmer","year":"2017","journal-title":"Ann Fam Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T14:06:29Z","timestamp":1575295589000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224580"}},"subtitle":[],"editor":[{"given":"Bart","family":"Ferket","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224580","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,12,2]]}}}